{"preliminary_commentary":{"by_channel":{"x_thread":17,"podcast":4,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05812807\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-21T14:51:07.378Z","note":"Automated from all 23 indexed sources (Apr 2022 – Jul 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":23,"text":"- Whether observation can replace adjuvant pembrolizumab after pCR to neoadjuvant chemotherapy plus pembrolizumab without losing benefit\n- Whether omitting adjuvant pembrolizumab spares immune-related adverse events such as adrenal insufficiency and hypophysitis\n- Which patients with pCR can safely omit adjuvant pembrolizumab, and whether MRD or ctDNA testing should guide it","kind":"questions"},"drugs_tested":[],"indication":"early-stage triple-negative breast cancer with pathologic complete response","name":"OptimICE-pCR","nct_id":"NCT05812807","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=optimice-pcr-nct05812807. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive pembrolizumab IV over 25-40 minutes Q3W or Q6W for 27 weeks. Patients also undergo tumor biopsy and collection of blood throughout the study. Patients also undergo mammography, breast ultrasound or MRI and during follow-up.","label":"Arm I (pembrolizumab)","type":"ACTIVE_COMPARATOR"},{"description":"Patients undergo observation for 27 weeks. Patients also undergo tumor biopsy and collection of blood throughout the study. Patients also undergo mammography, breast ultrasound or MRI during follow-up.","label":"Arm II (observation)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2033-05-31","type":"ESTIMATED"},"conditions":["Anatomic Stage II Breast Cancer AJCC v8","Early Stage Triple-Negative Breast Carcinoma","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8"],"enrollment":{"count":1295,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":["Keytruda"],"type":"BIOLOGICAL"},{"name":"Patient Observation","otherNames":["Active surveillance","watchful waiting","observation"],"type":"OTHER"},{"name":"Biopsy","otherNames":[],"type":"PROCEDURE"},{"name":"Biospecimen Collection","otherNames":[],"type":"PROCEDURE"},{"name":"Questionnaire Administration","otherNames":[],"type":"OTHER"},{"name":"Quality-of-Life Assessment","otherNames":[],"type":"OTHER"}],"last_update":"2026-08-05","lead_sponsor":"Alliance for Clinical Trials in Oncology","official_title":"OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2033-05-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Recurrence-free survival (RFS)","timeFrame":"Up to 10 years."}],"references":[],"start_date":{"date":"2023-06-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab","url":"https://clinicaltrials.gov/study/NCT05812807"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/optimice-pcr-nct05812807"}